In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

CHICAGO--(BUSINESS WIRE)--Relation Insurance Services (“Relation”) acquired the assets of Advantage Insurance Group. The transaction went into effect on May 31, 2025; terms of the transaction were not ...

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer. The ARASTEP trial is an international phase ...

Exercise is generally good for you, but a new high-quality clinical trial finds that it’s so good, it can even knock back colon cancer—and, in fact, rival some chemotherapy treatments. The finding ...

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

MOSCOW, 13 March (BelTA) - The relations between Russia and Belarus are developing in such a way that they can be considered an example for many other countries, Russian President Vladimir Putin said ...

Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis–associated organisms between partners suggests that ...